A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

Inclusion Criteria:

Patients with histologically or cytologically confirmed stage IIIB or stage IV advanced primary non-small cell lung cancinoma
Age 18 years or older

Exclusion Criteria:

Received investigational (not yet approved by a regulatory authority) or non-investigational agent to treat Lung Cancer
Received radiation therapy within 4 weeks before randomization
Major surgery within 4 weeks before randomization
Minor surgery within 2 weeks before randomizaiton
Systemic steroids within 1 week before randomization
Any grade 2 or greater neuropathy
History of severe (Grade 4) hypersensitivity reaction to products containing Cremophor EL (cyclosporine, teniposide)
History of any infection requiring hospitalization or antibiotics within 2 weeks before randomization
Known brain or spinal cord metastases
History of other cancers within 5 years before randomization
Known HIV, hepatitis-B or hepatitis-C infection
Pregnant or breast-feeding women
Previously treated with Mapatumumab